329 related articles for article (PubMed ID: 13679592)
1. Cardiac safety of liposomal anthracyclines.
Safra T
Oncologist; 2003; 8 Suppl 2():17-24. PubMed ID: 13679592
[TBL] [Abstract][Full Text] [Related]
2. Liposomal anthracyclines in metastatic breast cancer: clinical update.
Rivera E
Oncologist; 2003; 8 Suppl 2():3-9. PubMed ID: 13679590
[TBL] [Abstract][Full Text] [Related]
3. Cardiac safety of liposomal anthracyclines.
Ewer MS; Martin FJ; Henderson C; Shapiro CL; Benjamin RS; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):161-81. PubMed ID: 15717742
[TBL] [Abstract][Full Text] [Related]
4. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer.
Campos S
Oncologist; 2003; 8 Suppl 2():10-6. PubMed ID: 13679591
[TBL] [Abstract][Full Text] [Related]
5. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Theodoulou M; Hudis C
Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
[TBL] [Abstract][Full Text] [Related]
6. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
7. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.
Alberts DS; Muggia FM; Carmichael J; Winer EP; Jahanzeb M; Venook AP; Skubitz KM; Rivera E; Sparano JA; DiBella NJ; Stewart SJ; Kavanagh JJ; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):53-90. PubMed ID: 15717738
[TBL] [Abstract][Full Text] [Related]
9. Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.
Caballero Romero Á; Delgado Ureña MT; Salmerón García A; Megías Fernández MT; Librada Porriño-Bustamante M; Cabeza Barrera J
Anticancer Drugs; 2018 Oct; 29(9):821-826. PubMed ID: 30036190
[TBL] [Abstract][Full Text] [Related]
10. Liposomal anthracyclines for breast cancer.
Sparano JA; Winer EP
Semin Oncol; 2001 Aug; 28(4 Suppl 12):32-40. PubMed ID: 11552228
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
Rahman AM; Yusuf SW; Ewer MS
Int J Nanomedicine; 2007; 2(4):567-83. PubMed ID: 18203425
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T
Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068
[TBL] [Abstract][Full Text] [Related]
13. Liposomal anthracyclines for breast cancer: overview.
O'Shaughnessy J
Oncologist; 2003; 8 Suppl 2():1-2. PubMed ID: 13679589
[No Abstract] [Full Text] [Related]
14. Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma.
Pratt G; Wiles ME; Rawstron AC; Davies FE; Fenton JA; Proffitt JA; Child JA; Smith GM; Morgan GJ
Hematol Oncol; 1998 Jun; 16(2):47-55. PubMed ID: 10065112
[TBL] [Abstract][Full Text] [Related]
15. Liposomal anthracycline administration and toxicity management: a nursing perspective.
Wood LS
Semin Oncol; 2004 Dec; 31(6 Suppl 13):182-90. PubMed ID: 15717743
[TBL] [Abstract][Full Text] [Related]
16. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
18. Role of liposomal anthracyclines in the treatment of multiple myeloma.
Hussein MA; Anderson KC
Semin Oncol; 2004 Dec; 31(6 Suppl 13):147-60. PubMed ID: 15717741
[TBL] [Abstract][Full Text] [Related]
19. Cardiac safety of liposomal anthracyclines.
Batist G
Cardiovasc Toxicol; 2007; 7(2):72-4. PubMed ID: 17652807
[TBL] [Abstract][Full Text] [Related]
20. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]